{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T11:00:06Z","timestamp":1781953206393,"version":"3.54.5"},"reference-count":45,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":270,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2016YFC0901904 2021YFC2301502 2021YFF0703702 2023YFA0915501"],"award-info":[{"award-number":["2016YFC0901904 2021YFC2301502 2021YFF0703702 2023YFA0915501"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Science and Technology Innovation Action Plan","award":["NO. 23JS1401500"],"award-info":[{"award-number":["NO. 23JS1401500"]}]},{"name":"R&D Program of Guangzhou National Laboratory","award":["GZNL2024A01002"],"award-info":[{"award-number":["GZNL2024A01002"]}]},{"name":"Shanghai Municipal Science and Technology Major Project","award":["GTP"],"award-info":[{"award-number":["GTP"]}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2016YFC0901904 2021YFC2301502 2021YFF0703702 2023YFA0915501"],"award-info":[{"award-number":["2016YFC0901904 2021YFC2301502 2021YFF0703702 2023YFA0915501"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Science and Technology Innovation Action Plan","award":["NO. 23JS1401500"],"award-info":[{"award-number":["NO. 23JS1401500"]}]},{"name":"R&D Program of Guangzhou National Laboratory","award":["GZNL2024A01002"],"award-info":[{"award-number":["GZNL2024A01002"]}]},{"name":"Shanghai Municipal Science and Technology Major Project","award":["GTP"],"award-info":[{"award-number":["GTP"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Personalized medicine tailors treatments and dosages based on a patient\u2019s unique characteristics, particularly its genetic profile. Over the decades, stratified research and clinical trials have uncovered crucial drug-related information\u2014such as dosage, effectiveness, and side effects\u2014affecting specific individuals with particular genetic backgrounds. This genetic-specific knowledge, characterized by complex multirelationships and conditions, cannot be adequately represented or stored in conventional knowledge systems. To address these challenges, we developed CPMKG, a condition-based platform that enables comprehensive knowledge representation. Through information extraction and meticulous curation, we compiled 307\u2009614 knowledge entries, encompassing thousands of drugs, diseases, phenotypes (complications\/side effects), genes, and genomic variations across four key categories: drug side effects, drug sensitivity, drug mechanisms, and drug indications. CPMKG facilitates drug-centric exploration and enables condition-based multiknowledge inference, accelerating knowledge discovery through three pivotal applications. To enhance user experience, we seamlessly integrated a sophisticated large language model that provides textual interpretations for each subgraph, bridging the gap between structured graphs and language expressions. With its comprehensive knowledge graph and user-centric applications, CPMKG serves as a valuable resource for clinical research, offering drug information tailored to personalized genetic profiles, syndromes, and phenotypes.<\/jats:p>\n               <jats:p>Database URL: https:\/\/www.biosino.org\/cpmkg\/<\/jats:p>","DOI":"10.1093\/database\/baae102","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T15:20:37Z","timestamp":1727450437000},"source":"Crossref","is-referenced-by-count":9,"title":["CPMKG: a condition-based knowledge graph for precision medicine"],"prefix":"10.1093","volume":"2024","author":[{"given":"Jiaxin","family":"Yang","sequence":"first","affiliation":[{"name":"National Genomics Data Center & Bio-Med Big Data Center, Chinese Academy of Sciences Key Laboratory of Computational Biology, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences , Shanghai 200031,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhao","family":"Zhuang","sequence":"additional","affiliation":[{"name":"National Genomics Data Center & Bio-Med Big Data Center, Chinese Academy of Sciences Key Laboratory of Computational Biology, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences , Shanghai 200031,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenqi","family":"Li","sequence":"additional","affiliation":[{"name":"Shanghai Information Center for Life Sciences, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences , Shanghai 200031,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Xiong","sequence":"additional","affiliation":[{"name":"Shanghai Southgene Technology Co., Ltd. , Shanghai 201203,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Xu","sequence":"additional","affiliation":[{"name":"Shanghai Information Center for Life Sciences, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences , Shanghai 200031,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunchao","family":"Ling","sequence":"additional","affiliation":[{"name":"National Genomics Data Center & Bio-Med Big Data Center, Chinese Academy of Sciences Key Laboratory of Computational Biology, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences , Shanghai 200031,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8827-7546","authenticated-orcid":false,"given":"Guoqing","family":"Zhang","sequence":"additional","affiliation":[{"name":"National Genomics Data Center & Bio-Med Big Data Center, Chinese Academy of Sciences Key Laboratory of Computational Biology, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences , Shanghai 200031,","place":["China"]},{"name":"Shanghai Sixth People\u2019s Hospital , Shanghai 200233,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"key":"2024092715201304400_R1","doi-asserted-by":"publisher","DOI":"10.3390\/ph16111568","article-title":"Pharmacokinetics in pharmacometabolomics: towards personalized medication","volume":"16","author":"Jian","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"2024092715201304400_R2","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMp1006304","article-title":"The path to personalized medicine","volume":"363","author":"Hamburg","year":"2010","journal-title":"N Engl J Med"},{"key":"2024092715201304400_R3","doi-asserted-by":"publisher","first-page":"713","DOI":"10.2165\/00003088-200746090-00001","article-title":"Integrated pharmacokinetics and pharmacodynamics in drug development","volume":"46","author":"Dingemanse","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"2024092715201304400_R4","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2217\/pme-2016-0061","article-title":"European healthcare systems readiness to shift from \u2018one-size fits all\u2019 to personalized medicine","volume":"14","author":"Schee Genannt Halfmann","year":"2017","journal-title":"Per Med"},{"key":"2024092715201304400_R5","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.mjafi.2021.06.021","article-title":"Precision medicine: concept and tools","volume":"77","author":"Naithani","year":"2021","journal-title":"Med J Armed Forces India"},{"key":"2024092715201304400_R6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2174\/1389200215666140130124910","article-title":"Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process","volume":"15","author":"Caudle","year":"2014","journal-title":"Curr Drug Metab"},{"key":"2024092715201304400_R7","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/cpt.1651","article-title":"The Clinical Pharmacogenetics Implementation Consortium: 10 years later","volume":"107","author":"Relling","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"2024092715201304400_R8","article-title":"Pharmacogenomic biomarkers in US FDA-approved drug labels (2000-2020)","volume":"11","author":"Kim","year":"2021","journal-title":"J Pers Med"},{"key":"2024092715201304400_R9","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1097\/GIM.0b013e318238b38c","article-title":"Personalizing medicine with clinical pharmacogenetics","volume":"13","author":"Scott","year":"2011","journal-title":"Genet Med"},{"key":"2024092715201304400_R10","doi-asserted-by":"crossref","DOI":"10.1002\/wsbm.1417","article-title":"PharmGKB: a worldwide resource for pharmacogenomic information","volume":"10","author":"Barbarino","year":"2018","journal-title":"Wiley Interdiscip Rev Syst Biol Med"},{"key":"2024092715201304400_R11","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/toxsci\/kfad069","article-title":"CTD tetramers: a new online tool that computationally links curated chemicals, genes, phenotypes, and diseases to inform molecular mechanisms for environmental health","volume":"195","author":"Davis","year":"2023","journal-title":"Toxicol Sci"},{"key":"2024092715201304400_R12","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"2024092715201304400_R13","doi-asserted-by":"crossref","DOI":"10.1038\/sdata.2016.18","article-title":"The FAIR Guiding Principles for scientific data management and stewardship","volume":"3","author":"Wilkinson","year":"2016","journal-title":"Sci Data"},{"key":"2024092715201304400_R14","doi-asserted-by":"crossref","first-page":"D1090","DOI":"10.1093\/nar\/gky1042","article-title":"PreMedKB: an integrated precision medicine knowledgebase for interpreting relationships between diseases, genes, variants and drugs","volume":"47","author":"Yu","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"2024092715201304400_R15","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1055\/s-0038-1638845","article-title":"Formal ontologies in biomedical knowledge representation","volume":"22","author":"Anderson","year":"2013","journal-title":"Yearb Med Inform"},{"key":"2024092715201304400_R16","doi-asserted-by":"crossref","first-page":"D1075","DOI":"10.1093\/nar\/gkv1075","article-title":"The SIDER database of drugs and side effects","volume":"44","author":"Kuhn","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"2024092715201304400_R17","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/ng.3774","article-title":"CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer","volume":"49","author":"Griffith","year":"2017","journal-title":"Nat Genet"},{"key":"2024092715201304400_R18","doi-asserted-by":"crossref","first-page":"D1465","DOI":"10.1093\/nar\/gkad751","article-title":"TTD: Therapeutic Target Database describing target druggability information","volume":"52","author":"Zhou","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"2024092715201304400_R19","doi-asserted-by":"crossref","DOI":"10.1093\/database\/bau124","article-title":"DCDB 2.0: a major update of the drug combination database","volume":"2014","author":"Liu","year":"2014","journal-title":"Database (Oxford)"},{"key":"2024092715201304400_R20","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/nmeth.4000","article-title":"DoCM: a database of curated mutations in cancer","volume":"13","author":"Ainscough","year":"2016","journal-title":"Nat Methods"},{"key":"2024092715201304400_R21","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/JCP.0b013e3180a76dc0","article-title":"The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia","volume":"27","author":"Mulder","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"2024092715201304400_R22","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/tpj.2010.66","article-title":"Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study","volume":"12","author":"Risselada","year":"2012","journal-title":"Pharmacogenomics J"},{"key":"2024092715201304400_R23","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3109\/13651501.2014.957705","article-title":"HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis","volume":"18","author":"Ma","year":"2014","journal-title":"Int J Psychiatry Clin Pract"},{"key":"2024092715201304400_R24","article-title":"Personalized tacrolimus dose requirement by CYP3A5 but not ABCB1 or ACE genotyping in both recipient and donor after pediatric liver transplantation","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS One"},{"key":"2024092715201304400_R25","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/lt.20709","article-title":"Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients","volume":"12","author":"Wei-lin","year":"2006","journal-title":"Liver Transpl"},{"key":"2024092715201304400_R26","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1111\/bcp.12747","article-title":"Personalizing initial calcineurin inhibitor dosing by adjusting to donor CYP3A-status in liver transplant patients","volume":"80","author":"Monostory","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"2024092715201304400_R27","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1124\/jpet.110.173179","article-title":"Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin","volume":"335","author":"Bains","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"2024092715201304400_R28","doi-asserted-by":"crossref","first-page":"5470","DOI":"10.1074\/jbc.RA119.011385","article-title":"Inhibition of the erythropoietin-producing receptor EPHB4 antagonizes androgen receptor overexpression and reduces enzalutamide resistance","volume":"295","author":"Li","year":"2020","journal-title":"J Biol Chem"},{"key":"2024092715201304400_R29","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.vph.2018.02.002","article-title":"Bleeding predictors in patients following venous thromboembolism treated with vitamin K antagonists: association with increased number of single nucleotide polymorphisms","volume":"106","author":"Bryk","year":"2018","journal-title":"Vascul Pharmacol"},{"key":"2024092715201304400_R30","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1535-7163.MCT-13-0649","article-title":"KRAS mutation status is associated with enhanced dependency on folate metabolism pathways in non-small cell lung cancer cells","volume":"13","author":"Moran","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"2024092715201304400_R31","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3892\/mco.2013.118","article-title":"Methotrexate and gemcitabine combination chemotherapy for the treatment of malignant pleural mesothelioma","volume":"1","author":"Kuribayashi","year":"2013","journal-title":"Mol Clin Oncol"},{"key":"2024092715201304400_R32","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/clpt.2014.109","article-title":"Genetic variants in transcription factors are associated with the pharmacokinetics and pharmacodynamics of metformin","volume":"96","author":"Goswami","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"2024092715201304400_R33","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1210\/jc.2005-2323","article-title":"The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5\u02b9-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes","volume":"91","author":"Sesti","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2024092715201304400_R34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.gene.2014.04.004","article-title":"Assessment of clinical outcomes in breast cancer patients treated with taxanes: multi-analytical approach","volume":"543","author":"Tulsyan","year":"2014","journal-title":"Gene"},{"key":"2024092715201304400_R35","doi-asserted-by":"crossref","first-page":"9114","DOI":"10.18632\/oncotarget.24148","article-title":"Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients","volume":"9","author":"Tecza","year":"2018","journal-title":"Oncotarget"},{"key":"2024092715201304400_R36","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/tpj.2014.24","article-title":"Identification of SNPs associated with response of breast cancer patients to neoadjuvant chemotherapy in the EORTC-10994 randomized phase III trial","volume":"15","author":"Le Morvan","year":"2015","journal-title":"Pharmacogenomics J"},{"key":"2024092715201304400_R37","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.ejca.2013.11.028","article-title":"Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy","volume":"50","author":"Lee","year":"2014","journal-title":"Eur J Cancer"},{"key":"2024092715201304400_R38","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1158\/1078-0432.CCR-13-3232","article-title":"Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel","volume":"20","author":"Abraham","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2024092715201304400_R39","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1126\/science.2475911","article-title":"Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA","volume":"245","author":"Riordan","year":"1989","journal-title":"Science"},{"key":"2024092715201304400_R40","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jcf.2013.06.008","article-title":"Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function","volume":"13","author":"Van Goor","year":"2014","journal-title":"J Cyst Fibros"},{"key":"2024092715201304400_R41","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N Engl J Med"},{"key":"2024092715201304400_R42","doi-asserted-by":"crossref","first-page":"5613","DOI":"10.1021\/bi501007v","article-title":"Cystic fibrosis transmembrane conductance regulator (CFTR) potentiators protect G551D but not \u0394F508 CFTR from thermal instability","volume":"53","author":"Liu","year":"2014","journal-title":"Biochemistry"},{"key":"2024092715201304400_R43","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1053\/j.gastro.2013.11.007","article-title":"Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection","volume":"146","author":"Gane","year":"2014","journal-title":"Gastroenterology"},{"key":"2024092715201304400_R44","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1053\/j.gastro.2010.06.016","article-title":"Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction","volume":"139","author":"Thompson","year":"2010","journal-title":"Gastroenterology"},{"key":"2024092715201304400_R45","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nature08825","article-title":"ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C","volume":"464","author":"Fellay","year":"2010","journal-title":"Nature"}],"container-title":["Database"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/database\/article-pdf\/doi\/10.1093\/database\/baae102\/59376469\/baae102.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/database\/article-pdf\/doi\/10.1093\/database\/baae102\/59376469\/baae102.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T15:20:56Z","timestamp":1727450456000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/database\/article\/doi\/10.1093\/database\/baae102\/7780644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":45,"URL":"https:\/\/doi.org\/10.1093\/database\/baae102","relation":{},"ISSN":["1758-0463"],"issn-type":[{"value":"1758-0463","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024]]},"published":{"date-parts":[[2024]]},"article-number":"baae102"}}